The treatment of melanoma cells with the NAMPT inhibitor FK866 caused the production of ROS, blocked cancer cells at G2/M phase, leading to cell apoptosis, and improved mouse survival in a xenograft model, demonstrating that NAMPT is a therapeutic target in metastatic melanoma with BRAF mutation [20]. Here, NAMPT is linked to metastatic melanoma.